Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst remained upbeat on the "mega trends" driving the CPAP maker.Please watch the video ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

You can get the new Apple Watch in a variety of band and casing choices. This series introduces a jet black case — the Apple ...

For pediatric insomnia, Dr Umakanth Katwa and Dr Rafael Pelayo call for a blend of clinical expertise, behavioral therapy, and empathy.

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

Analyst Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...